The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons
Health Science Reports · 2024-06 · 7 (6)
DOI: 10.1002/hsr2.2165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 03.06.2024. Verfasst von Seyed Aria Nejadghaderi und 2 weiteren Autor:innen. Beteiligte Einrichtung: HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of…. Die Arbeit wurde bisher 259-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Critical appraisal or risk of bias assessment is a fundamental part of systematic reviews that clarifies the degree to which included research articles are qualified and reliable. Version 2 of the Cochrane tool for assessing the risk of bias in randomized trials (RoB 2), the updated version of the first tool, was released in 2019. Here, we have compared these two versions of Cochrane risk of bias assessment tools and highlighted the pros and cons of RoB 2.
Methods
Statistical analysis and methodology is not applicable to this article as no new data were created or analyzed in this study.
Results
The overall approach in RoB 2 is that by answering some signaling questions after the specification of results, effects of interest, and sources of information, an overall judgment for the quality of each study is reached. Accordingly, in the original version of the Cochrane RoB tool, the judgment can be in three different conclusions, including low, unclear, and high risk of bias. The most prominent difference in bias domains is the removal of “other bias” domain being replaced by “overall bias” judgment. Also, the most common presentation types of Cochrane risk of bias assessments are the “summary” and “graph” which are generated by Review Manager, web‐based applications, or packages in R software.
Conclusion
The RoB 2 tool, compared to the original RoB, has improved and is the recommended version by the Cochrane Collaboration for quality assessment of randomized controlled trials. It is recommended to consider funding source, duration of follow‐up, declaration of data availability, the status of baseline characteristics between groups, and sample size calculation methods in further revisions of the Cochrane risk of bias assessment tools.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of Medical Sciences Kerman Iran.
- Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN) Tehran Iran.
- Systematic Review and Meta-analysis Expert Group (SRMEG) Universal Scientific Education and Research Network (USERN) Tehran Iran.
- Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN) Chicago Illinois USA.
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN) Tehran Iran.
- Research Center for Immunodeficiencies, Children's Medical Center Tehran University of Medical Sciences Tehran Iran.
ORCID-Profile: Seyed Aria Nejadghaderi, Nima Rezaei
Zitieren
APA
Nejadghaderi, S. A., Balibegloo, M., & Rezaei, N. (2024). The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons. Health Science Reports, 7(6). https://doi.org/10.1002/hsr2.2165
Vancouver
Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons. Health Science Reports. 2024;7(6). doi:10.1002/hsr2.2165
BibTeX
@article{Nejadghaderi2024,
author = {Nejadghaderi, Seyed Aria and Balibegloo, Maryam and Rezaei, Nima},
title = {The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons},
journal = {Health Science Reports},
year = {2024},
volume = {7},
number = {6},
doi = {10.1002/hsr2.2165}
}
EUVIMED